SANUWAVE Health Inc

SANUWAVE Health Inc (SNWV) Stock Analysis

$2.210

-0.040 (-1.79%)At close

Loading chart…
High
2.650
Open
2.340
VWAP
2.32
Volume
361.26K
Mkt Cap
—
Low
2.105
Amount
838.71K
EV/EBITDA, TTM
-141.67

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others.

sanuwave.com

AI analysis of SANUWAVE Health Inc (SNWV)

Sell

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

Valuation Metrics

The current forward P/E ratio for SANUWAVE Health Inc (SNWV) is 18.25, compared to its 5-year average forward P/E of 21.60.

Forward P/E

Fair
5Y Average P/E
21.60
Current P/E
18.25
Overvalued
37.29
Undervalued
5.92

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-5.23
Current EV/EBITDA
-141.67
Overvalued
58.87
Undervalued
-69.32

Forward P/S

Undervalued
5Y Average P/S
2.63
Current P/S
0.30
Overvalued
4.90
Undervalued
0.35

Alphio AI Price Scenarios for SNWV

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SNWV

$40.32

Scenario price

B

Base

Base · 50%SNWV

$36.11

Scenario price

B

Bear

Bear · 25%SNWV

$28.03

Scenario price

Events Timeline

2026-11-05 (ET)

10:01:00

SANUWAVE Health Inc Trading Resumes

10:00:00

SANUWAVE Health Inc Trading Halted Due to Volatility

2026-07-13 (ET)

17:00:00

Sanuwave Health Q2 Revenue Expected to Reach $9.6M-$9.8M

2026-05-12 (ET)

17:10:00

Sanuwave Health Sees Q2 Revenue of $11.1M-$11.6M

17:10:00

Sanuwave Reports Q1 Revenue of $9.6M

News

SNWV FAQ — answered by Alphio AI

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others. It operates in the Healthcare sector.

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading